Neurocrine Biosciences, Inc. (NBIX) Our Analysis

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NBIXNeurocrine Biosciences, Inc.Follow NBIX — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 14.5B
P/E TTM: 20.9
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

Our verdict

Analyst

Our read on this company

The verdict, the score behind it and the written thesis are in Analyst.

Try it free for 7 days

Verdict over time

Analyst

Our read on this company

The verdict, the score behind it and the written thesis are in Analyst.

Try it free for 7 days

Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.